237 related articles for article (PubMed ID: 23340856)
1. From bone abnormalities to mineral metabolism dysregulation in autosomal dominant polycystic kidney disease.
Mekahli D; Bacchetta J
Pediatr Nephrol; 2013 Nov; 28(11):2089-96. PubMed ID: 23340856
[TBL] [Abstract][Full Text] [Related]
2. Evidence for Bone and Mineral Metabolism Alterations in Children With Autosomal Dominant Polycystic Kidney Disease.
De Rechter S; Bacchetta J; Godefroid N; Dubourg L; Cochat P; Maquet J; Raes A; De Schepper J; Vermeersch P; Van Dyck M; Levtchenko E; D'Haese P; Evenepoel P; Mekahli D
J Clin Endocrinol Metab; 2017 Nov; 102(11):4210-4217. PubMed ID: 29092060
[TBL] [Abstract][Full Text] [Related]
3. A decreased soluble Klotho level with normal eGFR, FGF23, serum phosphate, and FEP in an ADPKD patient with enlarged kidneys due to multiple cysts.
Kanai T; Shiizaki K; Betsui H; Aoyagi J; Yamagata T
CEN Case Rep; 2018 Nov; 7(2):259-263. PubMed ID: 29767399
[TBL] [Abstract][Full Text] [Related]
4. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and treatment.
Chang MY; Ong AC
Nephron Physiol; 2008; 108(1):p1-7. PubMed ID: 18075279
[TBL] [Abstract][Full Text] [Related]
5. Hepatic Production of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease.
Bienaimé F; Ambolet A; Aussilhou B; Brazier F; Fouchard M; Viau A; Barre P; Tissier AM; Correas JM; Paradis V; Terzi F; Friedlander G; Knebelmann B; Joly D; Prié D
J Clin Endocrinol Metab; 2018 Jun; 103(6):2319-2328. PubMed ID: 29618028
[TBL] [Abstract][Full Text] [Related]
6. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate.
Pavik I; Jaeger P; Kistler AD; Poster D; Krauer F; Cavelti-Weder C; Rentsch KM; Wüthrich RP; Serra AL
Kidney Int; 2011 Jan; 79(2):234-40. PubMed ID: 20944552
[TBL] [Abstract][Full Text] [Related]
7. Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity?
Bacchetta J; Salusky IB; Hewison M
Pediatr Nephrol; 2013 Apr; 28(4):577-82. PubMed ID: 23117582
[TBL] [Abstract][Full Text] [Related]
8. A distinct bone phenotype in ADPKD patients with end-stage renal disease.
Evenepoel P; Claes K; Cavalier E; Meijers B; Stenvinkel P; Behets G; Jankowska M; D'Haese P; Bammens B
Kidney Int; 2019 Feb; 95(2):412-419. PubMed ID: 30665572
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor 23 and soluble Klotho in patients with autosomal dominant polycystic kidney disease.
Akiyama K; Mochizuki T; Kataoka H; Tsuchiya K; Nitta K
Nephrology (Carlton); 2017 Nov; 22(11):848-853. PubMed ID: 27450645
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease.
Stubbs JR; He N; Idiculla A; Gillihan R; Liu S; David V; Hong Y; Quarles LD
J Bone Miner Res; 2012 Jan; 27(1):38-46. PubMed ID: 22031097
[TBL] [Abstract][Full Text] [Related]
11. Arterial dysfunction in early autosomal dominant polycystic kidney disease independent of fibroblast growth factor 23.
Yildiz A; Gul CB; Ersoy A; Asiltas B; Ermurat S; Dogan S; Karaagac K; Sag S; Oruc A; Aktas N; Ocakoglu G; Dogan I; Gullulu S; Gullulu M
Iran J Kidney Dis; 2014 Nov; 8(6):443-9. PubMed ID: 25362218
[TBL] [Abstract][Full Text] [Related]
12. Klotho Lacks an FGF23-Independent Role in Mineral Homeostasis.
Andrukhova O; Bayer J; Schüler C; Zeitz U; Murali SK; Ada S; Alvarez-Pez JM; Smorodchenko A; Erben RG
J Bone Miner Res; 2017 Oct; 32(10):2049-2061. PubMed ID: 28600880
[TBL] [Abstract][Full Text] [Related]
13. [ADPKD and intracranial aneurysms: indications for screening, follow-up and clinical management].
Econimo L; Zeni L; Cortinovis R; Alberici F; Izzi C; Scolari F
G Ital Nefrol; 2021 Oct; 38(5):. PubMed ID: 34713642
[TBL] [Abstract][Full Text] [Related]
14. High serum soluble α-Klotho levels in patients with autosomal dominant polycystic kidney disease.
Sari F; Inci A; Dolu S; Ellidag HY; Cetinkaya R; Ersoy FF
J Investig Med; 2017 Feb; 65(2):358-362. PubMed ID: 27733443
[TBL] [Abstract][Full Text] [Related]
15. Autosomal dominant policystic kidney disease, more than a renal disease.
Torra R
Minerva Endocrinol; 2014 Jun; 39(2):79-87. PubMed ID: 24736482
[TBL] [Abstract][Full Text] [Related]
16. Tubular STAT3 Limits Renal Inflammation in Autosomal Dominant Polycystic Kidney Disease.
Viau A; Baaziz M; Aka A; Mazloum M; Nguyen C; Kuehn EW; Terzi F; Bienaimé F
J Am Soc Nephrol; 2020 May; 31(5):1035-1049. PubMed ID: 32238474
[TBL] [Abstract][Full Text] [Related]
17. Autosomal Dominant Polycystic Kidney Disease: Extrarenal Involvement.
Righini M; Mancini R; Busutti M; Buscaroli A
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473800
[TBL] [Abstract][Full Text] [Related]
18. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease.
Spichtig D; Zhang H; Mohebbi N; Pavik I; Petzold K; Stange G; Saleh L; Edenhofer I; Segerer S; Biber J; Jaeger P; Serra AL; Wagner CA
Kidney Int; 2014 Jun; 85(6):1340-50. PubMed ID: 24402093
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization.
Liu S; Gupta A; Quarles LD
Curr Opin Nephrol Hypertens; 2007 Jul; 16(4):329-35. PubMed ID: 17565275
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease.
Gevers TJ; Chrispijn M; Wetzels JF; Drenth JP
BMC Nephrol; 2012 Apr; 13():17. PubMed ID: 22475206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
